The Pharmaceutical Industry: Tax Haven Manufacturing

Puerto Rico's pharmaceutical industry is the textbook case of colonial economic dependency — an economy restructured around a tax loophole, then devastated when the loophole closed.

Section 936 and the Pharmaceutical Boom:
- 1976: Congress created Section 936 of the Internal Revenue Code, allowing U.S. corporations to operate in Puerto Rico and repatriate profits to the mainland tax-free
- 1980s-1990s: Pharmaceutical companies flooded into Puerto Rico — Pfizer, Johnson & Johnson, Abbott, Baxter, Eli Lilly, Amgen, and dozens more
- By the late 1990s, Puerto Rico manufactured more pharmaceuticals than any U.S. state
- The island produced approximately 25% of all pharmaceuticals sold in the U.S.
- Top exports included blockbuster drugs: blood products, cardiovascular medications, antibiotics

The Numbers:
- At peak (early 2000s): ~30,000 direct pharmaceutical jobs
- Manufacturing represented ~46% of Puerto Rico's GDP
- Pharmaceutical exports exceeded $40 billion annually
- Puerto Rico became the 5th largest pharmaceutical jurisdiction in the world

The Colonial Structure:
1. Tax-driven, not market-driven: Companies came for the tax break, not Puerto Rico's workforce or infrastructure. The economic activity was artificial — dependent on a congressional decision, not organic development.
2. Profit extraction: While manufacturing happened in Puerto Rico, profits flowed to mainland corporate headquarters. The gap between GDP (what was produced on the island) and GNI (what Puerto Ricans actually earned) was enormous — as much as 30%.
3. Limited technology transfer: Companies brought finished processes to Puerto Rico for manufacturing. R&D, design, and corporate leadership remained on the mainland. Puerto Rico was a production floor, not an innovation center.
4. Environmental costs: Pharmaceutical manufacturing created toxic waste sites — several are now on the EPA Superfund list. Communities near plants experienced elevated cancer rates and contamination.
5. Wage suppression: While pharmaceutical jobs paid well relative to Puerto Rico's economy, they paid less than comparable mainland positions — a colonial wage differential.

The Collapse (Section 936 Repeal):
- 1996: Congress began phasing out Section 936 (fully eliminated by 2006)
- 2006-2010: Pharmaceutical companies began closing plants or reducing operations
- Puerto Rico lost approximately 30,000 manufacturing jobs
- The economic contraction triggered by Section 936's elimination is a direct cause of the debt crisis
- GDP contracted for more than a decade

The Lesson:
Section 936 demonstrates how colonial economies work: an external power creates economic conditions that serve its interests (cheap manufacturing + tax benefits), structures an entire territory's economy around that arrangement, then unilaterally changes the rules when it suits them — leaving the colony to absorb the consequences.

Puerto Rico didn't choose to become a pharmaceutical manufacturing center. Congress created the incentive. Puerto Rico didn't choose to lose pharmaceutical manufacturing. Congress eliminated the incentive. At no point did Puerto Rico control its own economic destiny.

Today: Pharmaceutical manufacturing remains significant but reduced. Puerto Rico still produces critical medications — the COVID-19 pandemic highlighted the island's role in the pharmaceutical supply chain. But the industry's contraction continues, and no replacement sector has emerged at comparable scale.